Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Darusentan (Abbott Laboratories).

G Y Lip1

  • 1Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine City Hospital, Birmingham, B18 7QH, UK. g.y.h.lip@bham.ac.uk

Idrugs : the Investigational Drugs Journal
|June 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State of play and future direction with NOACs: An expert consensus.

Vascular pharmacology·2018
Same author

Glycative and oxidative stress are associated with altered thrombus composition in diabetic patients with ST-elevation myocardial infarction.

International journal of cardiology·2017
Same author

Reply to Jolobe

The journal of the Royal College of Physicians of Edinburgh·2017
Same author

Clinical Stroke prevention in atrial fibrillation.

The journal of the Royal College of Physicians of Edinburgh·2017
Same author

Short runs of atrial arrhythmia and stroke risk: a European-wide online survey among stroke physicians and cardiologists.

The journal of the Royal College of Physicians of Edinburgh·2016
Same author

'Patient choice' concept in AF ESC Guidelines: is the clinician giving up? Reply.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2013
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Darusentan, an endothelin A antagonist, shows promise for treating congestive heart failure (CHF). Clinical trials indicate it effectively reduces key cardiovascular pressures in animal models.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Congestive heart failure (CHF) is a significant cardiovascular condition.
  • Endothelin A receptor antagonists are being investigated for therapeutic potential.

Purpose of the Study:

  • To evaluate darusentan, an endothelin A antagonist, as a potential treatment for congestive heart failure (CHF).

Main Methods:

  • Darusentan was tested in a monocrotaline-induced pulmonary hypertension model.
  • A canine model of CHF was used for chronic treatment studies.
  • In vitro assays determined receptor antagonism selectivity.

Main Results:

  • Darusentan significantly reduced right ventricular systolic pressure in pulmonary hypertension models.

Related Experiment Videos

  • In canine CHF models, it lowered left ventricular end diastolic pressure, mean pulmonary artery pressure, and right atrial pressure.
  • Darusentan demonstrated selective antagonism of the ET(A) receptor in vitro.

    • Conclusions:

    • Darusentan exhibits therapeutic potential for congestive heart failure.
    • Its efficacy in reducing cardiovascular pressures supports further investigation in clinical trials.